LONDON & WARREN, N.J.–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced a New Drug Submission (NDS) to Health Canada for the review and approval of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% – a once-daily, dual-agent (combination) eye drop – for the treatment of presbyopia in adults. Presbyopia is the gradual lo

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.